Current Issues in Bioavailability and Bioequivalence

When administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses, the rate and extent of absorption of the test drug does not show a significant difference from the rate and extent of absorption of the reference drug. Should the rate of absorption varies amongst products, it must be deliberate and stated in the proposed product label, and it must be clearly proved that it is not necessary for achieving effective body drug concentrations on chronic usage or that it is medically irrelevant for the drug. In practise, equivalence is defined as when key pharmacokinetic parameters required to determine the rate and scope of the test, as well as reference products, fall within a predetermined confidence interval. If a drug product is pharmaceutically comparable to the innovator product, meaning it has the same active ingredient, dosage form, strength, and method of administration, and is bioequivalent, the FDA determines it to be therapeutically equivalent. Therapeutically identical products can be used interchangeably. As a result, BE studies are viewed as surrogates for comparative clinical trials in order to determine therapeutic equivalence in terms of safety and efficacy between two pharmacological candidates.



 


  • Biotransformation
  • Physico-chemical factors
  • Energy dependent efflux transporters
  • CYP450 isozymes

Related Conference of Current Issues in Bioavailability and Bioequivalence

April 04-05, 2024

17th European Biosimilars Congress

Madrid, Spain
April 11-12, 2024

5th Annual Congress on Antibiotics and Bacterial Infections

Amsterdam, Netherlands
May 09-10, 2024

4th Global Summit on Pharmaceutical Research

Barcelona, Spain
May 16-17, 2024

18th World Drug Delivery Summit

Rome, Italy
May 30-31, 2024

9th Pharmaceutical Chemistry Conference

Paris, France
July 25-26, 2024

34th Annual European Pharma Congress

Frankfurt, Germany
September 11-12, 2024

9th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
September 25-26, 2024

4th World Congress on Rare Diseases & Orphan Drugs

Paris, France
November 26-27, 2024

3rd World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 26-27, 2024

3rd World Congress on Precision and Personalized Medicine

Zurich, Switzerland
November 28-29, 2024

39th World Congress on Pharmacology and Therapeutics

Paris, France
November 28-29, 2024

12th International Conference on Clinical Trials

Vancouver, Canada
December 05-06, 2024

17th World Drug Delivery Summit

Dubai, UAE

Current Issues in Bioavailability and Bioequivalence Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in